VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

Core Insights - VERAXA Biotech AG has announced a co-discovery alliance with OmniAb, Inc. to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors, combining their respective technologies for enhanced therapeutic discovery [1][2] - The collaboration is part of VERAXA's strategy to drive innovation through strategic partnerships, marking its second major initiative in six months [2] - Under the agreement, VERAXA will utilize OmniAb's transgenic antibody discovery solutions to source high-quality human antibody leads and will be responsible for preclinical validation of the bsADC lead candidate [2] Company Overview - VERAXA is focused on the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs and other innovative formats, leveraging transformative technologies and quality-by-design principles [3] - The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory, emphasizing its commitment to pioneering life science research [3] Business Combination - On April 22, 2025, VERAXA entered into a definitive business combination agreement with Voyager Acquisition Corp., which is expected to lead to VERAXA becoming a publicly traded company on NASDAQ [4] - Voyager Acquisition Corp. aims to revolutionize the healthcare sector through strategic mergers and business combinations, supported by a team with extensive expertise in investing and medical innovation [5]